AIMS: This randomized, crossover, single-dose study evaluated the relative oral bioavailability of posaconazole suspension and coprecipitate tablet formulations. Additionally, the study determined whether systemic exposure to posaconazole was affected by prandial status or by the fat content of a meal. METHODS: This was a randomized, open-label, four-way crossover, single-dose study in 20 healthy men. Posaconazole pharmacokinetics were evaluated over 72 h following a single oral dose of posaconazole suspension (200 mg/5 ml) administered with a high-fat meal, a nonfat breakfast, or after a 10 h fast, or posaconazole tablets (2 x 100 mg) administered with a high-fat meal. RESULTS: The posaconazole suspension showed a significant increase in bioavailability compared with the tablet (increase in AUC(0,72 h) = 137% (90% confidence interval (CI) 119%, 156% and Cmax = 123% (90% CI 104%, 146%). The mean increases in AUC(0,72 h) and Cmax values were about 400% when administered with a high-fat meal compared with administration of the suspension in the fasting state (AUC(0,72 h) 90% CI 343%, 448%; Cmax 90% CI 352%, 493%). Administration of the suspension with a nonfat meal enhanced exposure, resulting in an increase in AUC(0,72 h) of 264% (90% CI 231%, 302%) and in Cmax of 296% (90% CI 250%, 350%) relative to the fasted state. CONCLUSIONS: The suspension formulation of posaconazole was associated with enhanced systemic exposure and increased relative bioavailability compared with the tablet. Food substantially enhanced the rate and extent of posaconazole absorption in healthy subjects.
RCT Entities:
AIMS: This randomized, crossover, single-dose study evaluated the relative oral bioavailability of posaconazole suspension and coprecipitate tablet formulations. Additionally, the study determined whether systemic exposure to posaconazole was affected by prandial status or by the fat content of a meal. METHODS: This was a randomized, open-label, four-way crossover, single-dose study in 20 healthy men. Posaconazole pharmacokinetics were evaluated over 72 h following a single oral dose of posaconazole suspension (200 mg/5 ml) administered with a high-fat meal, a nonfat breakfast, or after a 10 h fast, or posaconazole tablets (2 x 100 mg) administered with a high-fat meal. RESULTS: The posaconazole suspension showed a significant increase in bioavailability compared with the tablet (increase in AUC(0,72 h) = 137% (90% confidence interval (CI) 119%, 156% and Cmax = 123% (90% CI 104%, 146%). The mean increases in AUC(0,72 h) and Cmax values were about 400% when administered with a high-fat meal compared with administration of the suspension in the fasting state (AUC(0,72 h) 90% CI 343%, 448%; Cmax 90% CI 352%, 493%). Administration of the suspension with a nonfat meal enhanced exposure, resulting in an increase in AUC(0,72 h) of 264% (90% CI 231%, 302%) and in Cmax of 296% (90% CI 250%, 350%) relative to the fasted state. CONCLUSIONS: The suspension formulation of posaconazole was associated with enhanced systemic exposure and increased relative bioavailability compared with the tablet. Food substantially enhanced the rate and extent of posaconazole absorption in healthy subjects.
Authors: Joseph Meletiadis; Jacques F G M Meis; Johan W Mouton; Juan Luis Rodriquez-Tudela; J Peter Donnelly; Paul E Verweij Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191
Authors: J A Barone; J G Koh; R H Bierman; J L Colaizzi; K A Swanson; M C Gaffar; B L Moskovitz; W Mechlinski; V Van de Velde Journal: Antimicrob Agents Chemother Date: 1993-04 Impact factor: 5.191
Authors: F Barchiesi; A M Schimizzi; F Caselli; D Giannini; V Camiletti; B Fileni; A Giacometti; L F Di Francesco; G Scalise Journal: J Antimicrob Chemother Date: 2001-12 Impact factor: 5.790
Authors: Gloria M González; Rolando Tijerina; Laura K Najvar; Rosie Bocanegra; Michael Rinaldi; David Loebenberg; John R Graybill Journal: Antimicrob Agents Chemother Date: 2002-05 Impact factor: 5.191
Authors: Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill Journal: Antimicrob Agents Chemother Date: 2002-05 Impact factor: 5.191
Authors: Paul O Gubbins; Gopal Krishna; Angela Sansone-Parsons; Scott R Penzak; Li Dong; Monika Martinho; Elias J Anaissie Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191
Authors: A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191
Authors: Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191
Authors: Gloria N Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Koller; Sherry Pierce; Deborah Blamble; Stefan Faderl; Lianchun Xiao; Mike Hernandez; Hagop Kantarjian Journal: Support Care Cancer Date: 2009-12-03 Impact factor: 3.603